Association of statin use and risk for severe headache or migraine by serum vitamin D status: A cross-sectional population-based study

Cephalalgia

Volumn 35, Issue 9, 2015, Pages 757-766

  Buettner, Catherine ^a,b   Burstein, Rami ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

25 hydroxy vitamin D; epidemiology; Headache; migraine; statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIFEDIOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; STEROID; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; HEADACHE; HUMAN; MALE; MIGRAINE; POPULATION RESEARCH; PREVALENCE; RISK FACTOR; SELF REPORT; UNITED STATES; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; MIDDLE AGED; MIGRAINE DISORDERS;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HEADACHE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PREVALENCE; VITAMIN D;

EID: 84937035304     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102414559733     Document Type: Article

References (58)

1. Rapoport D,. Unrecognized adverse drug reactions. CMAJ 1993; 149: 1233-1233.
2. Ramsey CS, Snyder QC,. Altitude-induced migraine headache secondary to pravastatin: Case report. Aviat Space Environ Med 1998; 69: 603-606.
3. Shuster J,. Lipid-lowering drugs and headache. Nursing 1998; 28: 32-32.
4. Liberopoulos EN, Mikhailidis DP,. Could statins be useful in the treatment of patients with migraine? Headache 2006; 46: 672-675.
5. Medeiros FL, Medeiros PL, Valença MM,. Simvastatin for migraine prevention. Headache 2007; 47: 855-856.
6. Kjaergaard M, Eggen AE, Mathiesen EB,. Association between headache and serum 25-hydroxyvitamin D: The Tromsø Study: Tromsø 6. Headache 2012; 52: 1499-1505.
7. Knutsen KV, Brekke M, Gjelstad S,. Vitamin D status in patients with musculoskeletal pain, fatigue and headache: A cross-sectional descriptive study in a multi-ethnic general practice in Norway. Scand J Prim Health Care 2010; 28: 166-171.
8. Prakash S, Shah ND,. Chronic tension-type headache with vitamin D deficiency: Casual or causal association? Headache 2009; 49: 1214-1222.
9. Zandifar A, Masjedi SS, Banihashemi M,. Vitamin D status in migraine patients: A case-control study. Biomed Res Int 2014; 2014: 514782-514782.
10. Palamaner Subash Shantha G, Ramos J, Thomas-Hemak L,. Association of vitamin D and incident statin induced myalgia-a retrospective cohort study. PloS One 2014; 9: e88877-e88877.
11. Dawson-Hughes B, Heaney RP, Holick MF,. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16: 713-716.
12. Thomas MK, Lloyd-Jones DM, Thadhani RI,. Hypovitaminosis D in medical inpatients. N Engl J Med 1998; 338: 777-783.
13. Centers for Disease Control and Prevention. National report on biochemical indicators of diet and nutrition in the U.S. population 1999-2002. Atlanta, GA, 2008.
14. Bischoff-Ferrari HA, Giovannucci E, Willett WC,. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84: 18-28.
15. National Health and Nutrition Examination Survey. Revised analytical note for NHANES 2000-2006 and NHANES III (1988-1994) 25-hydroxyvitamin D analysis, www.cdc.gov/nchs/data/nhanes/nhanes3/VitaminD-analyticnote.pdf. (2008, accessed 25 March 2014).
16. Silberstein SD, Holland S, Freitag F,. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337-1345.
17. Tepper SJ, Dahlof CG, Dowson A,. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: Data from the Landmark Study. Headache 2004; 44: 856-864.
18. Lipton RB, Bigal ME, Diamond M,. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343-349.
19. Schwartz BS, Stewart WF, Simon D,. Epidemiology of tension-type headache. JAMA 1998; 279: 381-383.
20. Vos T, Flaxman AD, Naghavi M,. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196.
21. Blumenfeld AM, Bloudek LM, Becker WJ,. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the second international burden of migraine study (IBMS-II). Headache 2013; 53: 644-655.
22. Sacco S, Ripa P, Grassi D,. Peripheral vascular dysfunction in migraine: A review. J Headache Pain 2013; 14: 80-80.
23. Schillaci G, Sarchielli P, Corbelli I,. Aortic stiffness and pulse wave reflection in young subjects with migraine: A case-control study. Neurology 2010; 75: 960-966.
24. Schürks M, Rist PM, Bigal ME,. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ 2009; 339: b3914-b3914.
25. Tietjen GE,. Migraine as a systemic vasculopathy. Cephalalgia 2009; 29: 987-996.
26. Baigent C, Keech A, Kearney PM,. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
27. Halcox JP, Deanfield JE,. Beyond the laboratory: Clinical implications for statin pleiotropy. Circulation 2004; 109 (21 Suppl): II42-II48.
28. Kanaki AI, Sarafidis PA, Georgianos PI,. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013; 26: 608-616.
29. Moon GJ, Kim SJ, Cho YH,. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol 2014; 10: 140-147.
30. Tziomalos K, Karagiannis A, Athyros VG,. Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure. Curr Pharm Des 2014; 20: 6306-6313.
31. Undas A, Brummel-Ziedins KE, Mann KG,. Anticoagulant effects of statins and their clinical implications. Thromb Haemost 2014; 111: 392-400.
32. Tietjen GE, Herial NA, White L,. Migraine and biomarkers of endothelial activation in young women. Stroke 2009; 40: 2977-2982.
33. Perini F, D'Andrea G, Galloni E,. Plasma cytokine levels in migraineurs and controls. Headache 2005; 45: 926-931.
34. Tietjen GE, Al-Qasmi MM, Athanas K,. Increased von Willebrand factor in migraine. Neurology 2001; 57: 334-336.
35. Fidan I, Yuksel S, Ymir T,. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol 2006; 171: 184-188.
36. Yetkin E, Ozisik H, Ozcan C,. Increased dilator response to nitrate and decreased flow-mediated dilatation in migraineurs. Headache 2007; 47: 104-110.
37. Vanmolkot FH, Van Bortel LM, de Hoon JN,. Altered arterial function in migraine of recent onset. Neurology 2007; 68: 1563-1570.
38. Jiménez Caballero PE, Muñoz Escudero F,. Peripheral endothelial function and arterial stiffness in patients with chronic migraine: A case-control study. J Headache Pain 2013; 14: 8-8.
39. Liman TG, Neeb L, Rosinski J,. Peripheral endothelial function and arterial stiffness in women with migraine with aura: A case-control study. Cephalalgia 2012; 32: 459-466.
40. Schillaci G, Sarchielli P, Corbelli I,. Aortic stiffness and pulse wave reflection in young subjects with migraine: A case-control study. Neurology 2010; 75: 960-966.
41. Nagai T, Tabara Y, Igase M,. Migraine is associated with enhanced arterial stiffness. Hypertens Res 2007; 30: 577-583.
42. Wang CY, Liu PY, Liao JK,. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med 2008; 14: 37-44.
43. Tousoulis D, Oikonomou E, Siasos G,. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227: 367-372.
44. Shishehbor MH, Brennan ML, Aviles RJ,. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003; 108: 426-431.
45. Chu AY, Guilianini F, Barratt BJ,. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ Cardiovasc Genet 2012; 5: 58-65.
46. Clockaerts S, Van Osch GJ, Bastiaansen-Jenniskens YM,. Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam study. Ann Rheum Dis 2012; 71: 642-647.
47. Kadam UT, Blagojevic M, Belcher J,. Statin use and clinical osteoarthritis in the general population: A longitudinal study. J Gen Intern Med 2013; 28: 943-949.
48. Gouveia TL, Scorza FA, Iha HA,. Lovastatin decreases the synthesis of inflammatory mediators during epileptogenesis in the hippocampus of rats submitted to pilocarpine-induced epilepsy. Epilepsy Behav 2014; 36: 68-73.
49. Undas A, Brummel KE, Musial J,. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
50. Scher AI, Terwindt GM, Picavet HS,. Cardiovascular risk factors and migraine: The GEM population-based study. Neurology 2005; 64: 614-620.
51. Monastero R, Pipia C, Cefalù AB,. Association between plasma lipid levels and migraine in subjects aged >or =50 years: Preliminary data from the Zabùt Aging Project. Neurol Sci 2008; 29 (Suppl 1): S179-S181.
52. Kurth T, Ridker PM, Buring JE,. Migraine and biomarkers of cardiovascular disease in women. Cephalalgia 2008; 28: 49-56.
53. Gruber HJ, Bernecker C, Pailer S,. Lipid profile in normal weight migraineurs-evidence for cardiovascular risk. Eur J Neurol 2010; 17: 419-425.
54. Rist PM, Tzourio C, Kurth T,. Associations between lipid levels and migraine: Cross-sectional analysis in the epidemiology of vascular ageing study. Cephalalgia 2011; 31: 1459-1465.
55. de Boer IH, Levin G, Robinson-Cohen C,. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: A cohort study. Ann Intern Med 2012; 156: 627-634.
56. Müller K, Haahr PM, Diamant M,. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992; 4: 506-512.
57. Canning MO, Grotenhuis K, de Wit H,. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001; 145: 351-357.
58. Ashina S, Bendtsen L, Lyngberg AC, et al. Prevalence of neck pain in migraine and tension-type headache: A population study. Cephalalgia. Epub ahead of print 22 May 2014.